Examining muscle function in patients with interstitial lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the relationship between skeletal muscle function and symptoms like dyspnea and exercise intolerance in patients with interstitial lung disease (ILD). It aims to compare the muscle function of ILD patients to healthy controls, assess how muscle fatigue affects their breathing and exercise capacity, and evaluate the impact of supplemental oxygen on these factors. By understanding these dynamics, the study seeks to provide insights into the role of muscle dysfunction in ILD and its effects on patient quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria for ILD Patients:

* Age 40-80 years (inclusive)
* A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses
* Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis
* Appropriate candidate for pulmonary rehabilitation
* 6 minute walk distance 50m or more
* Oxygen saturation ≥ 92% by pulse oximetry at rest while breathing room air
* Clinically stable for the preceding 6 weeks
* Can fluently read and write in English

Inclusion Criteria for Healthy Controls:

* Age 40-80 (inclusive)
* Normal pulmonary function (80-120% predicted)
* No lung or cardiovascular disease
* Can fluently read and write in English

Exclusion Criteria for the ILD patients:

* Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease)
* Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation
* Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25%
* Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program
* Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit
* Significant emphysema (less than 10% volume on HRCT or FEV1/FVC less than 0.70)

Exclusion Criteria for Healthy Controls:

* Currently smoking or previously smoked more than 10 pack-years
* Any medical conditions that prevents them for exercising safely
* Cardiac pacemaker or any metal or electronic inside the body

Where it's running

• St. Paul's Hospital
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Jordan A Guenette, PhD — University of British Columbia
• Study coordinator: Olivia Ferguson, MSc
• Email: Olivia.Ferguson@hli.ubc.ca
• Phone: 1-604-806-8835

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biobank for interstitial lung diseases

  This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas · NCT05392881

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Beetroot Juice for IPF Patients: A Pilot Test of Nitrate-Rich Supplementation

  This small pilot tests whether nitrate-rich beetroot juice twice daily for 3 days can affect exercise responses in adults with idiopathic pulmonary fibrosis.

  Recruiting University Hospital Southampton NHS Foundation Trust · Southampton · NCT06488638

• Testing hymecromone in adults with interstitial lung disease

  This study is testing a new medication called hymecromone to see if it can help adults with progressive interstitial lung disease feel better and improve their lung function.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Research Triangle Park, North Carolina · NCT06325696

• Registry for individuals affected by pulmonary fibrosis

  This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.

  Recruiting Pulmonary Fibrosis Foundation · Chicago, Illinois · NCT05382572

• New IPF drug ORJ-001 tested in adults with IPF

  A phase 2 study tests ORJ-001 versus placebo in adults with idiopathic pulmonary fibrosis to see if it is tolerated and whether it helps lung function.

  Recruiting at 2 sites Phase 2 Oorja Bio, Inc. · Doral, Florida and 1 other locations · NCT07869147

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.